Literature DB >> 9925551

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.

M E Jones1, M R Visser, M Klootwijk, P Heisig, J Verhoef, F J Schmitz.   

Abstract

The activities of eight fluoroquinolones and linezolid, quinupristin-dalfopristin (Synercid), gentamicin, and vancomycin were tested against 96 ciprofloxacin-susceptible and 205 ciprofloxacin-resistant Staphylococcus aureus strains. Overall, clinafloxacin, followed by moxifloxacin and trovafloxacin, was the most active quinolone tested. For all isolates, linezolid and quinupristin-dalfopristin showed activities that were at least comparable to vancomycin, with no cross-resistance to any other test compound.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9925551      PMCID： PMC89096     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

Authors:  D Felmingham; M J Robbins; K Ingley; I Mathias; H Bhogal; A Leakey; G L Ridgway; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Specific information concerning taxonomy, pathogenicity and methicillin resistance of staphylococci obtained by a multiplex PCR.

Authors:  F J Schmitz; C R Mackenzie; B Hofmann; J Verhoef; M Finken-Eigen; H P Heinz; K Köhrer
Journal:  J Med Microbiol       Date:  1997-09       Impact factor: 2.472

3.  In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

Authors:  A Dalhoff; U Petersen; R Endermann
Journal:  Chemotherapy       Date:  1996 Nov-Dec       Impact factor: 2.544

4.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

5.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

6.  RP 59500: a proposed mechanism for its bactericidal activity.

Authors:  M Aumercier; S Bouhallab; M L Capmau; F Le Goffic
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

Review 7.  Epidemiology of quinolone resistance: Europe and North and South America.

Authors:  F W Goldstein; J F Acar
Journal:  Drugs       Date:  1995       Impact factor: 9.546

8.  Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.

Authors:  M R Visser; M Rozenberg-Arska; H Beumer; I M Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

9.  In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  K R Smith; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

10.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.

Authors:  K P Fu; S C Lafredo; B Foleno; D M Isaacson; J F Barrett; A J Tobia; M E Rosenthale
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191
View more
  18 in total

1.  Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Authors:  H J Linde; M Schmidt; E Fuchs; U Reischl; H H Niller; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 5.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 7.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

9.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  In vitro activity of the new quinolone WCK 771 against staphylococci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noel J De Souza; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.